GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biodexa Pharmaceuticals Plc (NAS:BDRX) » Definitions » Total Equity

Biodexa Pharmaceuticals (Biodexa Pharmaceuticals) Total Equity : $5.92 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biodexa Pharmaceuticals Total Equity?

Biodexa Pharmaceuticals's total equity for the quarter that ended in Dec. 2023 was $5.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Biodexa Pharmaceuticals Total Equity Historical Data

The historical data trend for Biodexa Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodexa Pharmaceuticals Total Equity Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.63 9.03 13.90 3.85 5.92

Biodexa Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.90 9.23 3.85 6.69 5.92

Biodexa Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biodexa Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=13.344-7.423
=5.92

Biodexa Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=13.344-7.423
=5.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biodexa Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of Biodexa Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Biodexa Pharmaceuticals (Biodexa Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Biodexa Pharmaceuticals (Biodexa Pharmaceuticals) Headlines

From GuruFocus

Appeal of Delisting Determination

By sperokesalga sperokesalga 06-20-2023

Midatech Pharma PLC Announces Results of General Meeting

By ACCESSWIRE ACCESSWIRE 03-24-2023

Results of Annual General Meeting and General Meeting

By sperokesalga sperokesalga 06-14-2023

Midatech Pharma PLC Announces Result of General Meeting

By ACCESSWIRE ACCESSWIRE 01-23-2023

Posting of Annual Report & Notice of AGM

By sperokesalga sperokesalga 05-22-2023

Midatech Pharma PLC Announces Receipt of NASDAQ Notice

By ACCESSWIRE ACCESSWIRE 02-03-2023

Results of Appeal of Delisting Determination

By Marketwired 07-06-2023